RT Journal Article
SR Electronic
T1 The Serological Sciences Network (SeroNet) for COVID-19: Depth and Breadth of Serology Assays and Plans for Assay Harmonization
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.27.22271399
DO 10.1101/2022.02.27.22271399
A1 Karger, Amy B.
A1 Brien, James D.
A1 Christen, Jayne M.
A1 Dhakal, Santosh
A1 Kemp, Troy J.
A1 Klein, Sabra L.
A1 Pinto, Ligia A.
A1 Premkumar, Lakshmanane
A1 Roback, John D.
A1 Binder, Raquel A.
A1 Boehme, Karl W.
A1 Boppana, Suresh
A1 Crawford, James M.
A1 Daiss, John L.
A1 Dupuis, Alan P.
A1 Espino, Ana M.
A1 Forconi, Catherine
A1 Forrest, J. Craig
A1 Girardin, Roxie C.
A1 Haddad, Natalie S.
A1 Heaney, Christopher D.
A1 Hunt, Danielle T.
A1 Kennedy, Joshua L.
A1 King, Christopher L.
A1 Kruczynski, Kate
A1 LaBaer, Joshua
A1 Lee, F. Eun-Hyung
A1 Lee, William T.
A1 Liu, Shan-Lu
A1 Lozanski, Gerard
A1 Moormann, Ann M.
A1 Murugan, Vel
A1 Okoye, Nkemakonam C.
A1 Pantoja, Petraleigh
A1 Payne, Anne F.
A1 Park, Jin
A1 Pinninti, Swetha
A1 Pinto, Amelia K.
A1 Pisanic, Nora
A1 Qiu, Ji
A1 Sariol, Carlos A.
A1 Song, Lusheng
A1 Steffen, Tara L.
A1 Stone, E. Taylor
A1 Styer, Linda M.
A1 Suthar, Mehul S.
A1 Thomas, Stefani N.
A1 Thyagarajan, Bharat
A1 Yates, Jennifer L.
A1 Sobhani, Kimia
YR 2022
UL http://medrxiv.org/content/early/2022/03/01/2022.02.27.22271399.abstract
AB Background In October 2020, the National Cancer Institute (NCI) Serological Sciences Network (SeroNet) was established to study the immune response to COVID-19, and “to develop, validate, improve, and implement serological testing and associated technologies.” SeroNet is comprised of 25 participating research institutions partnering with the Frederick National Laboratory for Cancer Research (FNLCR) and the SeroNet Coordinating Center. Since its inception, SeroNet has supported collaborative development and sharing of COVID-19 serological assay procedures and has set forth plans for assay harmonization.Methods To facilitate collaboration and procedure sharing, a detailed survey was sent to collate comprehensive assay details and performance metrics on COVID-19 serological assays within SeroNet. In addition, FNLCR established a protocol to calibrate SeroNet serological assays to reference standards, such as the U.S. SARS-CoV-2 serology standard reference material and First WHO International Standard (IS) for anti-SARS-CoV-2 immunoglobulin (20/136), to facilitate harmonization of assay reporting units and cross-comparison of study data.Results SeroNet institutions reported development of a total of 27 ELISA methods, 13 multiplex assays, 9 neutralization assays, and use of 12 different commercial serological methods. FNLCR developed a standardized protocol for SeroNet institutions to calibrate these diverse serological assays to reference standards.Conclusions SeroNet institutions have established a diverse array of COVID-19 serological assays to study the immune response to SARS-CoV-2 virus and vaccines. Calibration of SeroNet serological assays to harmonize results reporting will facilitate future pooled data analyses and study cross-comparisons.Competing Interest StatementA.B.K. is a consultant for Roche Diagnostics and has received research support from Siemens Healthcare Diagnostics and Kyowa Kirin Pharmaceutical Development. J.D.B., A.K.P., E.T.S., and T.L.S. have received research support from Altimmune. J.D.R. and M.S.S. are co-inventors on a patent filed by Emory University covering the serology assay described in this manuscript. M.S.S. serves on the advisory board for Moderna and Ocugen. F.E.L. is the founder of MicroB-plex, Inc. J.L.D. is the CSO of MicroB-plex, Inc. N.S.H. has been a senior scientist at MicroB-plex, Inc. F.E.L. has research grants from the Gates Foundation and Genentech, is on the SAB of Be Biopharma, Inc., and received royalties from BLI, Inc., as an inventor for the plasma cell survival media. S.B. has research support from Merck and Pfizer, and is a member of the CMV Vaccine Advisory Committees of Merck and Moderna. S.P. has research support from Moderna. All remaining authors report no relevant conflicts of interest.Funding StatementThis study was funded by: U54CA260591, U01CA260584, U01CA260469, U54CA260543, U54CA260560, U54CA260582, U54CA260492, U01CA260541, U01CA261277, U01CA261277, U01CA260526, U01CA261276, U01CA260539, U01CA260513, U01CA260462, CBC21X089, CBC21X090, CBC21X091, CBC21X092Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.